What is PRISMM?

A researcher in the lab

Patient Response to Immunotherapy using Spliceosome Mutational Markers (PRISMM) is a novel trial offered through Johns Hopkins, designed for patients with advanced cancers whose tumors have been sequenced and carry a specific rare mutation (SF3B1, U2AF1 or SRSF2). 

This clinical trial is now closed.

The principal investigator will be Dr. Cesar Santa-Maria. The IRB number is IRB00186535.